Skip to main content

Scheduled maintenance

Location search will not be available from Sunday, April 12 at 9:00 PM EDT until Sunday, April 12 at 11:00 PM EDT due to planned site maintenance. We apologize for any inconvenience.

Hide
Quest Diagnostics

A Retrospective Review of Mitochondrial Genome NGS Analysis in 7000 Rare Disease Patients

Mitochondrial Medicine - Therapeutic Development

MMTD 2022

London, UK, November 21 - 23 , 2022

Poster presentation: A retrospective review of mitochondrial genome NGS analysis in 7000 rare disease patients

Authors: Lukke M, Valori M, Kytölä V, Siivonen P, Salmenperä P, Gentile M, Liaquat K, Myllykangas S, Koskenvuo J, Isokallio M

Specialties: Genetics

Disclaimer:  One or more of the authors of this publication were employed at the time by Blueprint Genetics, a subsidiary of Quest Diagnostics.

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2026 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.